Skip to content
Roboearth – Lifestyle
Author:
Ranok Therapeutics
/C O R R E C T I O N — Ranok Therapeutics/
June 1, 2026
Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026
June 1, 2026
Ranok Therapeutics Announces the Publication of Positive Phase 1a Clinical Results for KRAS G12D Inhibitor RNK08954 in Cancer Discovery
May 11, 2026